Navigation Links
Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Date:3/7/2008

SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it will release financial results for the three and twelve months ended December 31, 2007 after market close on Thursday, March 13, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, March 14, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 38622372.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The co
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
2. Halozyme Therapeutics Amends Stockholder Rights Plan
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
5. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
6. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
7. ExonHit Therapeutics - 2007 Financial Results
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Technology Products (ACAMP) hosts, health ... - Today ACAMP hosted a health & medical ... microfluidics can play a powerful role in the ... health and improve the quality, cost and outcomes ...
(Date:12/3/2009)... 3 ACCESS PHARMACEUTICALS, INC. ... update on its European commercial launch of MuGard, an ... effect of radiation treatment and chemotherapy. MuGard is commercially ... including the UK, Germany, Italy, Norway, Greece and Sweden. ...
(Date:12/3/2009)... 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ... drug discovery and life sciences research, today introduced Living ... Living Image software drives the more than 800 Caliper ... 4.0 features advanced spectral unmixing tools to enhance fluorescent ...
(Date:12/2/2009)... announces that a new market research report ... Carbondioxide Incubators - A Global Market Perspective ... Incubators are the most critical equipment used ... applications for providing a controlled environment to ...
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... Luminex Corporation,(Nasdaq: LMNX ) today announced that ... Forum to be held October 9-11,2007, in San ... Balthrop, president and chief,executive officer, and Harriss T. ... Pacific time; 12:30 p.m. Eastern time on Thursday,October ...
... GENZ ) confirmed today that it will not change ... $5.60 in cash per,outstanding common share as set forth ... owns approximately 22 percent of the,outstanding shares of Bioenvision ... its preferred stock that carry a unique set of,rights ...
... Set for October, JACKSONVILLE, Fla., Sept. 27 ... "Company") announced today that its,performance/vitality beverage product, AQUISS(TM), ... California to the Oregon border. 7-Eleven,plans a launch ... an,aggressive sampling campaign to acquaint 7-Eleven,s customers with ...
Other Biology Technology:Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 3Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores 2
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
(Date:12/3/2009)... that staph infections are caused by many bacterial cells that ... called quorum sensing because many bacteria must be present to ... has determined that the very first stage of staph infection, ... occurs in a single cell and that this individual process ...
(Date:12/3/2009)... in the design of the upcoming forest deal at Copenhagen ... scientist at the University of Leeds. , Writing today ... least 50% of the carbon credit payments to be agreed ... Degredation), should be made to forest dwellers directly, and their ...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Cancer Drugs Emerging as Top Driver of Specialty Drug Spending 5319 1Cancer Drugs Emerging as Top Driver of Specialty Drug Spending 5319 2Cancer Drugs Emerging as Top Driver of Specialty Drug Spending 5319 3Cancer Drugs Emerging as Top Driver of Specialty Drug Spending 5319 4Electronic Payment Exchange Welcomes New Visa Best Practices for Data Field Encryption 59123 1Electronic Payment Exchange Welcomes New Visa Best Practices for Data Field Encryption 59123 2Electronic Payment Exchange Welcomes New Visa Best Practices for Data Field Encryption 59123 3Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 14393 1Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 14393 2
... Distinct genetic profiles can discern different groups of ... which the body turns against itself, Dartmouth Medical ... subtypes within the disease offers new insight into ... to treat illness and opens a window for ...
... some northern tree species to disappear in the future, ... expand their range northward as soon as the conditions ... nearly so simple. A model developed by University of ... that while certain northern species, such as balsam fir, ...
... Johns Hopkins Kimmel Cancer Center researchers have identified ... with a deadly combination of,traditional mutations and "smothered" ... patients. , The Hopkins team showed that this ... of breast and colon,cancer by disrupting biochemical pathways ...
Other Biology News:Dartmouth researchers discover gene signatures for scleroderma 2Dartmouth researchers discover gene signatures for scleroderma 3Scattered nature of Wisconsin's woodlands could complicate forests' response to climate change 2'Smothered' genes combine with mutations to yield poor outcome in cancer patients 2
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The EZ DNA Methylation Kit uses ... method for DNA methylation analysis. The kit ... that takes place between cytosine and sodium ... The EZ DNA Methylation Kits innovative in-column ...
... rat adult and fetal tissue, ... * T75 plated cells $750.00, ... This product requires Celprogen Stem ... and extracellular matrix, * E55007-08-T25 ...
... ideally suited as an initial cloning host ... screening capability (with appropriate plasmids) and recA ... of excellent quality plasmid DNA. The DE3 ... a stringent host due to the presence ...
Biology Products: